Eli Lilly and Company (LLY)

In the past six months (August 2025 - February 2026), Eli Lilly's stock has experienced notable events. The company's stock price saw a modest increase, demonstrating resilience in a volatile market. In November 2025, Eli Lilly reached a $1 trillion market capitalization, becoming the first healthcare company globally to achieve this milestone. On February 4, 2026, Eli Lilly reported strong financial results for the fourth quarter of 2025, with revenue increasing by 43% to $19.3 billion, surpassing forecasts. On February 5, 2026, Eli Lilly's stock declined by 4% following news that Hims & Hers Health Inc. was introducing a competitive, lower-priced version of Novo Nordisk's Wegovy pill. Despite this, Eli Lilly's Q4 2025 earnings beat expectations, leading to a stock jump of 9% on February 5, 2026.

While specific product seasonality is not explicitly detailed, the demand for Eli Lilly's products, particularly Mounjaro and Zepbound, has been described as "unprecedented" and "strong," leading to significant investments in expanding manufacturing capacity. The company's Q4 2025 results showed substantial volume increases both in the U.S. and internationally. From a stock performance perspective, February has historically shown a chance of being a "green month" for LLY.

Eli Lilly and Company is a global pharmaceutical company focused on researching, developing, manufacturing, and commercializing pharmaceutical products for humans and animals. The company's key therapeutic areas include diabetes, oncology, immunology, and neuroscience. Major products include Tirzepatide (Mounjaro and Zepbound) for diabetes, weight loss and sleep apnea, Abemaciclib (Verzenio) for breast cancer, Dulaglutide (Trulicity) for diabetes, Ixekizumab (Taltz) for autoimmune diseases, Empagliflozin (Jardiance) for diabetes, Insulin lispro (Humalog) and Insulin (Humulin), Ramucirumab (Cyramza) for cancer treatment, Baricitinib (Olumiant) for rheumatoid arthritis, alopecia areata, and COVID-19, and Galcanezumab (Emgality) for migraine prevention. The company has also had success with drugs like Cialis, Prozac, and Zyprexa, which are now off-patent.

Eli Lilly has a significant global presence, with offices in 18 countries and products sold in approximately 125 countries. The company has operations and a commercial presence across North America, Europe, Asia, and other regions, serving both developed and emerging markets. In 2024, 67% of the company's revenues originated from the United States. Eli Lilly also has considerable R&D and manufacturing facilities in five European countries (Spain, France, Ireland, Italy, and Germany) and nine other countries globally. Clinical research is conducted in 55 different countries.

In the past year, Eli Lilly has made strategic moves that could positively impact its brand reputation, particularly concerning access and affordability of its medications. In August 2024, Eli Lilly announced a direct-to-consumer (DTC) strategy for its weight management medication, Zepbound, offering it at a significantly lower price than competitors through its website. Additionally, Eli Lilly is joining the TrumpRx initiative, which provides discounted cash prices on approximately 40 drugs, allowing consumers to purchase medications directly at reduced costs with a TrumpRx coupon.

Eli Lilly and Company has 5,440 institutional owners and shareholders. Major institutional owners include Lilly Endowment Inc., which holds 10.26% of the company's shares. Other significant institutional holders are The Vanguard Group, Inc., BlackRock, Inc., The PNC Financial Services Group, Inc., Capital Research and Management Company, and State Street Global Advisors, Inc.